» Articles » PMID: 39644067

Challenges in Hospice and End-of-life Care in the Transfusion-dependent Patient

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Despite promising advances leading to improved survival, many patients with hematologic malignancies end up dying from their underlying disease. Their end-of-life (EOL) care experience is often marked by worsening symptoms, late conversations about patient values, increased healthcare utilization, and infrequent involvement of palliative care and hospice services. There are several challenges to the delivery of high-quality EOL care that span across disease, patient, clinician, and system levels. These barriers include an unpredictable prognosis, the patient's prognostic misunderstandings and preference to focus on the immediate future, and the oncologist's hesitancy to initiate EOL conversations. Additionally, many patients with hematologic malignancies have increasing transfusion requirements at the end of life. The hospice model often does not support ongoing blood transfusions for patients, creating an additional and substantial hurdle to hospice utilization. Ultimately, patients who are transfusion-dependent and elect to enroll in hospice do so often within a limited time frame to benefit from hospice services. Strategies to overcome challenges in EOL care include encouraging repeated patient-clinician conversations that set expectations and incorporate the patient's goals and preferences and promoting multidisciplinary team collaboration in patient care. Ultimately, policy-level changes are required to improve EOL care for patients who are transfusion-dependent. Many research efforts to improve the care of patients with hematologic malignancies at the end of life are underway, including studies directed toward patients dependent on transfusions.

References
1.
McCaughan D, Roman E, Smith A, Garry A, Johnson M, Patmore R . Palliative care specialists' perceptions concerning referral of haematology patients to their services: findings from a qualitative study. BMC Palliat Care. 2018; 17(1):33. PMC: 5822662. DOI: 10.1186/s12904-018-0289-1. View

2.
Odejide O, Salas Coronado D, Watts C, Wright A, Abel G . End-of-life care for blood cancers: a series of focus groups with hematologic oncologists. J Oncol Pract. 2014; 10(6):e396-403. PMC: 5706135. DOI: 10.1200/JOP.2014.001537. View

3.
Odejide O, Cronin A, Condron N, Fletcher S, Earle C, Tulsky J . Barriers to Quality End-of-Life Care for Patients With Blood Cancers. J Clin Oncol. 2016; 34(26):3126-32. DOI: 10.1200/JCO.2016.67.8177. View

4.
Lowe J, Yu Y, Wolf S, Samsa G, LeBlanc T . A Cohort Study of Patient-Reported Outcomes and Healthcare Utilization in Acute Myeloid Leukemia Patients Receiving Active Cancer Therapy in the Last Six Months of Life. J Palliat Med. 2018; 21(5):592-597. PMC: 5963667. DOI: 10.1089/jpm.2017.0463. View

5.
Fletcher S, Cronin A, Zeidan A, Odejide O, Gore S, Davidoff A . Intensity of end-of-life care for patients with myelodysplastic syndromes: Findings from a large national database. Cancer. 2016; 122(8):1209-15. DOI: 10.1002/cncr.29913. View